Skip to content
Search

Latest Stories

Haris Sohail: We need to forget that we are playing India

Pakistan do not need any added motivation for their Champions Trophy opener against India but batsman Haris Sohail insists his team has to forget about the opposition it is facing in the marquee clash on Sunday (4).

Rain at Edgbaston curtailed Pakistan s final warm-up game before the start of the tournament, with Australia making 57 for one batting first in 10 overs on Monday.


For Pakistan, the focus now shifts to taking on India on Sunday in the opening pool encounter at the same ground. While those encounters usually provide a little extra spice, Haris urged his team not to get carried with the rivalry.

And when Sunday rolls around, the 28-year-old, who came in as a replacement for Umar Akmal, is confident Pakistan will have adjusted to the weather conditions, having had a fortnight on English soil.

He said: "We have had good preparation, we have had a good couple of days. It is a huge game against India, a really big game.

"But it is just a game.

"We are preparing ourselves for all of the hard matches.

"Our strength is our bowling and fielding and we are working on all these aspects of our game.

"It is difficult for us but we have had good preparation to adapt to English conditions but we have been here for 10 days before our first game and we have five days more before our first game."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less